Skip to main content

Advertisement

SpringerLink
Log in

Management of type 2 diabetes in patients with heart failure

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Diabetes mellitus and heart failure (HF) commonly coexist, and together these conditions are associated with increased morbidity and mortality compared with either condition alone. Although the optimal treatment strategy to achieve glucose control in HF patients with type 2 diabetes has not been well studied, given the common coexistence of these conditions and the need to adequately treat hyperglycemia to prevent microvascular complications, it is important for clinicians to understand the potential implications of diabetic therapy in patients with established HF. Until recently, metformin was contraindicated in patients with HF because of the potential risk of lactic acidosis; however, recent retrospective studies of metformin use in HF patients have shown that this medication may be used safely and indeed may be beneficial in patients with stable HF. The association between thiazolidinediones (TZDs) and HF remains controversial, but recent prospective randomized trials of TZD use in HF patients suggest that worsening volume retention associated with these agents may lead to worsening of HF symptoms. The recently developed incretin-based therapies, such as exenatide and sitagliptin, also have not been extensively studied in HF populations; however, small pilot studies of glucagon-like peptide-1 have shown potential promise in the treatment of diabetic patients with HF. Although they may be difficult to perform, future randomized controlled trials are needed to establish optimal treatment goals and strategies in this population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hunt SA, Abraham WT, Chin MH, et al.: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154–e235.

    Article  PubMed  Google Scholar 

  2. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76–79.

    Article  PubMed  Google Scholar 

  3. Centers for Disease Control and Prevention: National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf. Accessed June 2008.

  4. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; the National Heart, Lung, and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association. Circulation 1999, 100:1132–1133.

  5. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035–2038.

    Article  PubMed  CAS  Google Scholar 

  6. Nichols GA, Gullion CM, Koro CE, et al.: The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004, 27:1879–1884.

    Article  PubMed  Google Scholar 

  7. Kostis JB, Sanders M: The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens 2005, 18:731–737.

    Article  PubMed  CAS  Google Scholar 

  8. MacDonald MR, Petrie MC, Hawkins NM, et al.: Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008, 29:1224–1240.

    Article  PubMed  CAS  Google Scholar 

  9. Adams KF Jr, Fonarow GC, Emerman CL, et al.: Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149:209–216.

    Article  PubMed  Google Scholar 

  10. From AM, Leibson CL, Bursi F, et al.: Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 2006, 119:591–599.

    Article  PubMed  Google Scholar 

  11. Bertoni AG, Hundley WG, Massing MW, et al.: Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004, 27:699–703.

    Article  PubMed  Google Scholar 

  12. Vaur L, Gueret P, Lievre M, et al.: Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care 2003, 26:855–860.

    Article  PubMed  Google Scholar 

  13. Nichols GA, Koro CE, Gullion CM, et al.: The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005, 21:51–57.

    Article  PubMed  CAS  Google Scholar 

  14. Iribarren C, Karter AJ, Go AS, et al.: Glycemic control and heart failure among adult patients with diabetes. Circulation 2001, 103:2668–2673.

    PubMed  CAS  Google Scholar 

  15. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405–412.

    Article  PubMed  CAS  Google Scholar 

  16. Cheung N, Wang JJ, Rogers SL, et al.: Diabetic retinopathy and risk of heart failure. J Am Coll Cardiol 2008, 51:1573–1578.

    Article  PubMed  Google Scholar 

  17. Boudina S, Abel ED: Diabetic cardiomyopathy revisited. Circulation 2007, 115:3213–3223.

    Article  PubMed  Google Scholar 

  18. MacDonald MR, Petrie MC, Varyani F, et al.: Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008, 29:1377–1385.

    Article  PubMed  Google Scholar 

  19. Murcia AM, Hennekens CH, Lamas GA, et al.: Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004, 164:2273–2279.

    Article  PubMed  Google Scholar 

  20. Shekelle PG, Rich MW, Morton SC, et al.: Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a metaanalysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529–1538.

    Article  PubMed  CAS  Google Scholar 

  21. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837–853.

  22. Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.

    Article  PubMed  CAS  Google Scholar 

  23. Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  24. Bhatia V, Wilding GE, Dhindsa G, et al.: Association of poor glycemic control with prolonged hospital stay in patients with diabetes admitted with exacerbation of congestive heart failure. Endocr Pract 2004, 10:467–471.

    PubMed  Google Scholar 

  25. Masoudi FA, Inzucchi SE, Wang Y, et al.: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111:583–590.

    Article  PubMed  CAS  Google Scholar 

  26. Eurich DT, Majumdar SR, McAlister FA, et al.: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28:2345–2351.

    Article  PubMed  CAS  Google Scholar 

  27. Cleveland JC Jr, Meldrum DR, Cain BS, et al.: Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997, 96:29–32.

    PubMed  CAS  Google Scholar 

  28. Meier JJ, Gallwitz B, Schmidt WE, et al.: Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004, 90:9–12.

    Article  PubMed  CAS  Google Scholar 

  29. Misbin RI: Phenformin-associated lactic acidosis: pathogenesis and treatment. Ann Intern Med 1977, 87:591–595.

    PubMed  CAS  Google Scholar 

  30. Misbin RI, Green L, Stadel BV, et al.: Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998, 338:265–266.

    Article  PubMed  CAS  Google Scholar 

  31. Misbin RI: The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 2004, 27:1791–1793.

    Article  PubMed  Google Scholar 

  32. Inzucchi SE, Masoudi FA, McGuire DK: Metformin in heart failure. Diabetes Care 2007, 30:e129.

    Article  PubMed  Google Scholar 

  33. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004, 351:1106–1118.

    Article  PubMed  Google Scholar 

  34. Staels B, Fruchart JC: Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005, 54:2460–2470.

    Article  PubMed  CAS  Google Scholar 

  35. Pistrosch F, Passauer J, Fischer S, et al.: In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004, 27:484–490.

    Article  PubMed  CAS  Google Scholar 

  36. Takano H, Nagai T, Asakawa M, et al.: Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000, 87:596–602.

    PubMed  CAS  Google Scholar 

  37. Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129–1136.

    Article  PubMed  CAS  Google Scholar 

  38. Aguilar D, Bozkurt B, Pritchett A, et al.: The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol 2007, 50:32–36.

    Article  PubMed  CAS  Google Scholar 

  39. Dargie HJ, Hildebrandt PR, Riegger GA, et al.: A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007, 49:1696–1704.

    Article  PubMed  CAS  Google Scholar 

  40. Giles TD, Miller AB, Elkayam U, et al.: Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 2008, 14:445–452.

    Article  PubMed  CAS  Google Scholar 

  41. Zhang H, Zhang A, Kohan DE, et al.: Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A 2005, 102:9406–9411.

    Article  PubMed  CAS  Google Scholar 

  42. Guan Y, Hao C, Cha DR, et al.: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005, 11:861–866.

    Article  PubMed  CAS  Google Scholar 

  43. Karalliedde J, Buckingham R, Starkie M, et al.: Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006, 17:3482–3490.

    Article  PubMed  CAS  Google Scholar 

  44. Nesto RW, Bell D, Bonow RO, et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003, 108:2941–2948.

    Article  PubMed  Google Scholar 

  45. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.

    Article  PubMed  CAS  Google Scholar 

  46. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.

    Article  PubMed  CAS  Google Scholar 

  47. Pocock SJ, Wang D, Pfeffer MA, et al.: Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006, 27:65–75.

    Article  PubMed  Google Scholar 

  48. Egan JM, Meneilly GS, Habener JF, Elahi D: Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002, 87:3768–3773.

    Article  PubMed  CAS  Google Scholar 

  49. Meneilly GS, McIntosh CH, Pederson RA, et al.: Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 2001, 24:1951–1956.

    Article  PubMed  CAS  Google Scholar 

  50. Yoo BK, Triller DM, Yoo DJ: Exenatide: a new option for the treatment of type 2 diabetes. Ann Pharmacother 2006, 40:1777–1784.

    Article  PubMed  CAS  Google Scholar 

  51. Nikolaidis LA, Elahi D, Shen YT, Shannon RP: Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289:H2401–H2408.

    Article  PubMed  CAS  Google Scholar 

  52. Sokos GG, Nikolaidis LA, Mankad S, et al.: Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694–699.

    Article  PubMed  CAS  Google Scholar 

  53. Nikolaidis LA, Mankad S, Sokos GG, et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962–965.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Baylor College of Medicine, 1709 Dryden Street-BCM 620, Suite 500, Box 13, Houston, TX, 77030, USA

    David Aguilar

Authors
  1. David Aguilar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Aguilar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aguilar, D. Management of type 2 diabetes in patients with heart failure. Curr Treat Options Cardio Med 10, 465–475 (2008). https://doi.org/10.1007/s11936-008-0039-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-008-0039-4

Keywords

Search

Navigation